SCTR: Secretin receptor
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
G protein-coupled receptor activated by secretin (SCT), which is involved in different processes such as regulation of the pH of the duodenal content, food intake and water homeostasis.
- Drugs that act on it: 3
- Approved: 3
- In phases 1 to 3: 0
- Sponsors: 2
Who Is On It, and How Far Along
Every drug ChEMBL records acting on SCTR, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Secretin receptor agonist.| Secretin | Approved | Ferring Pharmaceuticals | Protein or peptide | Agonist | — | 12 | — |
| Secretin synthetic human | Approved | Chirhoclin | Protein or peptide | Agonist | — | 12 | — |
| Secretin synthetic porcine | Approved | Chirhoclin | Protein or peptide | Agonist | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.| Secretin in Ex-situ Liver Perfusion | Secretin, Secretin synthetic human | Phase 1 / Phase 2 | Enrolling by invitation | Erasmus Medical Center | 2026-06-16 |
| A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects | Secretin, Secretin synthetic human | Phase 4 | Active, not recruiting | Mayo Clinic | 2025-12-16 |
| The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma | Secretin, Secretin synthetic human | — | Not yet recruiting | Charles University, Czech Republic | 2025-02-04 |
| The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas) | Secretin, Secretin synthetic human | — | Enrolling by invitation | Adenocyte, LLC | 2024-02-26 |
| The LINFU® U.S. Registry for the in the General Population Without Risk Factors | Secretin, Secretin synthetic human | — | Not yet recruiting | Adenocyte, LLC | 2024-02-26 |
| The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease | Secretin, Secretin synthetic human | — | Not yet recruiting | Adenocyte, LLC | 2024-02-26 |
| Imaging Biomarkers of Pancreatic Function and Disease | Secretin, Secretin synthetic human | Phase 4 | Enrolling by invitation | Children's Hospital Medical Center, Cincinnati | 2022-12-21 |
| Secretin in Refeeding | Secretin, Secretin synthetic human | — | Recruiting | University of California, Los Angeles | 2022-02-11 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Type 2 diabetes mellitus
- 0.52
- Gastrin-producing neuroendocrine tumor
- 0.38
- Neurodegenerative disease
- 0.37
- Autism
- 0.35
- Rheumatic disorder
- 0.20
- Cardiac transplant
- 0.20
- Neuroendocrine neoplasm
- 0.19
- Schizophrenia
- 0.07
- Familial idiopathic steroid-resistant nephrotic syndrome
- 0.07
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1925, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P47872, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets